10-Q: Notable Labs Reports Second Quarter 2024 Financial Results and Provides Business Update

Notable Labs reports its financial results for the second quarter ended June 30, 2024, highlighting ongoing efforts in predictive medicine development.

Summary

• Notable Labs, a clinical-stage platform therapeutics company, is focused on developing predictive medicines for cancer patients.
• The company's Predictive Medicines Platform (PMP) aims to predict individual patient responses to cancer treatments ex vivo.
• Notable's lead asset, Volasertib, is in Phase 2 study preparation for relapsed/refractory AML (r/r AML), with initial safety data expected in Q4 2024 and efficacy data in H1 2025.
• Notable is co-developing Fosciclopirox with CicloMed LLC for AML patients, based on PMP's pre-clinical application.
• The company is actively seeking additional assets for in-licensing to expand its development pipeline.
• As of June 30, 2024, Notable had cash of $4.1 million and an accumulated deficit of $91.3 million.
• The company needs additional capital to fund operations and intends to raise capital through debt or equity issuance.
• Notable received a Nasdaq notification on July 17, 2024, regarding non-compliance with the minimum bid price requirement.
• The company has until January 13, 2025, to regain compliance with Nasdaq's minimum bid price requirement.
• Services revenue increased from $0 to $2 thousand for the three months ended June 30, 2024 compared to the three months ended June 30, 2023.
• Services revenue increased from $0 to $3 thousand for the six months ended June 30, 2024 compared to the six months ended June 30, 2023.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While there's progress in clinical development and revenue generation, the financial situation and Nasdaq compliance issues raise concerns.

Positives

• Notable's PMP platform has shown promising results in predicting patient responses to cancer treatments.
• The company is advancing Volasertib into a Phase 2 clinical trial, with potential for initial data readouts in the near term.
• Notable is expanding its pipeline through co-development and in-licensing activities.
• Services revenue increased from $0 to $2 thousand for the three months ended June 30, 2024 compared to the three months ended June 30, 2023.
• Services revenue increased from $0 to $3 thousand for the six months ended June 30, 2024 compared to the six months ended June 30, 2023.

Negatives

• Notable has a significant accumulated deficit of $91.3 million as of June 30, 2024.
• The company's cash position is $4.1 million as of June 30, 2024, raising concerns about its ability to fund operations.
• Notable received a Nasdaq notification regarding non-compliance with the minimum bid price requirement, potentially leading to delisting.
• The company has incurred losses and negative cash flows from operations since its inception.

Risks

• Notable's ability to continue as a going concern is dependent on securing additional financing and achieving profitable operations.
• Failure to regain compliance with Nasdaq's minimum bid price requirement could adversely affect the liquidity of ordinary shares and the ability to raise additional capital.
• Clinical trials may encounter delays or fail to demonstrate safety and efficacy.
• Regulatory approval for product candidates is not guaranteed.
• The market price of ordinary shares may be highly volatile.

Future Outlook

Notable expects to continue to incur significant and increasing operating losses at least for the foreseeable future and does not expect positive cash flows from operations in the foreseeable future.

Management Comments

• Notable is actively preparing to initiate our Phase 2 study in relapsed/refractory AML (r/r AML).
• We anticipate initial Phase 2 safety data to begin reading out in the fourth quarter of 2024 with the first patient cohort completion in the first quarter of 2025.
• We expect initial efficacy data in the first half of 2025.

Industry Context

The announcement reflects a trend in the pharmaceutical industry towards precision medicine and predictive diagnostics to improve clinical trial outcomes and drug development efficiency.

Comparison to Industry Standards

• The 97% clinical response rate in PMP predicted responders is significantly higher than typical response rates in cancer clinical trials, which often range from 10% to 30% in unselected patient populations.
• Companies like Foundation Medicine and Guardant Health also focus on precision medicine, but Notable's PMP platform uses a different approach by measuring biological responses rather than relying solely on genetic biomarkers.
• Other companies developing therapies for AML, such as Agios Pharmaceuticals and Celgene (now part of Bristol Myers Squibb), may be considered competitors, but Notable's predictive approach could offer a competitive advantage.

Management Changes

Related Party Transactions

• For consulting services with the Board Member, the Company recorded general and administrative expenses of $ 65,691 and $ 128,250 for the three and six months ended June 30, 2024 and $ 61,623 and $ 105,401 for the three and six months ended June 30, 2023.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings.
• Employees may be affected by potential cost-cutting measures if the company fails to secure additional funding.
• Patients could benefit from successful development of predictive medicines.
• Creditors face increased risk due to the company's financial challenges.

Next Steps

• Initiate Phase 2 study in relapsed/refractory AML (r/r AML).
• Read out initial Phase 2 safety data in Q4 2024.
• Complete first patient cohort in Q1 2025.
• Obtain initial efficacy data in H1 2025.
• Seek additional assets for in-licensing to expand the development pipeline.
• Monitor closing bid price for ordinary shares and consider options to resolve Nasdaq non-compliance.

Key Dates

Keywords

predictive medicine, cancer, volasertib, fosciclopirox, clinical trials, PMP, AML, Nasdaq, financial results, Notable Labs